Endoxifen and hTra2-beta1 regulate estrogen receptor α alternative splicing pattern in breast cancer cells

Background: Endoxifen acts as a selective estrogen receptor modulator by blocking ERα transcriptional activity. Alternatively spliced ERα mRNA variants are present in normal and malignant breast tissues, possessing the potential for increased estrogen activities. Human Tra2-β1 is a splicing factor regulating splicing processes in a sequence-specific and concentration-dependent manner. hTra2-β1 intracellular localization may vary during cancer progression or is changed by exogenic stimuli, e.g. therapeutic drugs. Here we analyzed the potential impacts of endoxifen and hTra2-β1 on ERα expression pattern and the ef…